Sanctuary Advisors LLC Makes New $181,000 Investment in LeMaitre Vascular, Inc. (NASDAQ:LMAT)

Sanctuary Advisors LLC bought a new stake in LeMaitre Vascular, Inc. (NASDAQ:LMAT) during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The firm bought 1,948 shares of the medical instruments supplier’s stock, valued at approximately $181,000.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. NBC Securities Inc. boosted its stake in shares of LeMaitre Vascular by 73.2% in the 3rd quarter. NBC Securities Inc. now owns 433 shares of the medical instruments supplier’s stock valued at $40,000 after purchasing an additional 183 shares in the last quarter. USA Financial Formulas acquired a new stake in LeMaitre Vascular in the third quarter valued at approximately $60,000. nVerses Capital LLC grew its stake in shares of LeMaitre Vascular by 33.3% during the second quarter. nVerses Capital LLC now owns 800 shares of the medical instruments supplier’s stock worth $66,000 after buying an additional 200 shares during the last quarter. GAMMA Investing LLC lifted its stake in shares of LeMaitre Vascular by 34.3% in the 3rd quarter. GAMMA Investing LLC now owns 736 shares of the medical instruments supplier’s stock valued at $68,000 after acquiring an additional 188 shares during the last quarter. Finally, Van ECK Associates Corp acquired a new stake in shares of LeMaitre Vascular during the 2nd quarter valued at $75,000. 84.64% of the stock is currently owned by institutional investors and hedge funds.

LeMaitre Vascular Trading Up 0.1 %

Shares of LeMaitre Vascular stock opened at $92.95 on Tuesday. The stock has a fifty day simple moving average of $98.02 and a 200 day simple moving average of $90.68. LeMaitre Vascular, Inc. has a 12-month low of $52.88 and a 12-month high of $109.58. The company has a market capitalization of $2.09 billion, a P/E ratio of 50.79, a price-to-earnings-growth ratio of 2.47 and a beta of 0.93.

LeMaitre Vascular (NASDAQ:LMAT) last issued its quarterly earnings data on Thursday, October 31st. The medical instruments supplier reported $0.49 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.44 by $0.05. LeMaitre Vascular had a net margin of 19.40% and a return on equity of 13.15%. The business had revenue of $54.82 million during the quarter, compared to the consensus estimate of $53.50 million. During the same period in the prior year, the firm posted $0.33 EPS. The firm’s quarterly revenue was up 15.6% compared to the same quarter last year. On average, analysts predict that LeMaitre Vascular, Inc. will post 1.94 EPS for the current year.

LeMaitre Vascular Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Thursday, December 5th. Investors of record on Thursday, November 21st were paid a $0.16 dividend. The ex-dividend date of this dividend was Thursday, November 21st. This represents a $0.64 annualized dividend and a yield of 0.69%. LeMaitre Vascular’s payout ratio is 34.97%.

Insider Buying and Selling at LeMaitre Vascular

In related news, Director Bridget A. Ross sold 3,750 shares of the firm’s stock in a transaction that occurred on Friday, November 15th. The shares were sold at an average price of $101.47, for a total value of $380,512.50. Following the completion of the transaction, the director now directly owns 2,278 shares of the company’s stock, valued at approximately $231,148.66. This trade represents a 62.21 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 10.79% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

A number of research firms have weighed in on LMAT. StockNews.com lowered shares of LeMaitre Vascular from a “buy” rating to a “hold” rating in a report on Friday, December 13th. Cantor Fitzgerald began coverage on LeMaitre Vascular in a report on Tuesday, October 15th. They issued a “neutral” rating and a $96.00 price objective for the company. Oppenheimer reaffirmed an “outperform” rating and set a $93.00 target price (up from $90.00) on shares of LeMaitre Vascular in a report on Friday, November 1st. Finally, Barrington Research increased their price target on LeMaitre Vascular from $92.00 to $93.00 and gave the company an “outperform” rating in a research note on Friday, November 1st. Three equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, LeMaitre Vascular currently has an average rating of “Moderate Buy” and an average target price of $94.57.

LeMaitre Vascular Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.